Ignite Creation Date:
2024-05-05 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00143312
Status:
COMPLETED
Last Update Posted:
2009-10-06
First Post:
2005-08-31
Brief Title:
Voriconazole for Secondary Prophylaxis of Invasive Fungal Infections in Patients With Allogeneic Stem Cell Transplants
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
Prospective Open-Label Non-Comparative Multicenter Study for the Secondary Prophylaxis of Invasive Fungal Infections IFI With Voriconazole in Patients With Allogeneic Stem Cell Transplants SCT
Status:
COMPLETED
Status Verified Date:
2009-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
VOSIFI
Brief Summary:
To prevent recurrence of invasive fungal infection in patients with allogeneic stem cell transplants
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None